
Daiichi Sankyo aims to launch 5 ADC therapies in Korea by 2030
Daiichi Sankyo Korea has unveiled plans to introduce five antibody-drug conjugate (ADC) therapies by 2030, as part of its strategy to reinforce its leadership in the global oncology market. The announcement was made during the company’s “Science & …